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ABSTRACT 
 
In this study we investigated the metabolism, i.e. remodelling and translocation, of the 
aminophospholipids phosphatidylserine (PS) and phosphatidylethanolamine (PE). A new method for 
introduction of exogenous PS and PE molecular species to cultured cells was developed, and 
combined with mass spectrometry it enabled more detailed follow-up of the metabolism of single 
molecular species than was possible previously.  
 
We found that I) exogenous PS and PE molecular species can be efficiently introduced to cultured 
cells without compromising cell integrity, II) PS and PE molecular species are remodelled by several 
phospholipases displaying selectivity based on phopholipid head group and acyl chain composition, 
III) PS decarboxylase (PSD) and the Kennedy pathways provide a different PE molecular species 
composition  to  the  cellular  PE  pool.  In  addition,  PE  species  produced  by  these  pathways  are  
translocated from the site of synthesis to other cell compartments depending on their acyl chain 
composition. 
 
The data obtained in the present study helps to understand cellular phospholipid metabolism in more 
depth. The data show that effective labelling of cultured cells by exogenous phospholipids does not 
compromise cell viability and may be used to disturb cellular phospholipid composition to study lipid 
homeostasis. Remodelling and translocation of PS and PE molecular species is highly selective. The 
developed method and mass- spectrometric techniques may be used in future studies to understand 
disturbances in lipid homeostasis for example in diabetes mellitus, thus opening doors to optional 
scientific approaches for studying the mechanisms behind pathologies related to lipid disturbances. 
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INTRODUCTION 
 
Mammalian cells and subcellular organelles are enclosed by membranes consisting of hundreds of 
different lipid species and proteins. Lipids also store energy, regulate the activity of some proteins and 
serve as second messengers in signal transduction (or as sources of such messengers), e.g. the platelet 
activating factor and eicosanoids [1, 2]. 
 
It has been estimated that mammalian cell membranes contain over 1000 different types of lipid 
molecules differing in the head group and acyl chains [3]. Phospholipids define the fluidity of the 
membrane, regulate its properties as well as the properties of embedded proteins [3]. Phospholipids are 
also present in heterogeneities referred to as lipid rafts [4, 5].  
 
The most abundant phospholipid in mammalian cells is phosphatidylcholine, comprising 40-50% of 
the total phospholipids [3]. Phosphatidylethanolamine and phosphatidylserine comprise 15-25% and 
2-10% of the total cellular phospholipids while the other phospholipid classes, phophatidylinositol, 
sphingomyelin, cardiolipin, phosphatidic acid and glycosphingolipids comprise 10-15%, 5-10%, 2-
5%, 1-2% and 2-5% respectively [3]. The properties of the different phospholipids, for example those 
of the head groups influence membranes in diverse ways. Phosphatidylethanolamine in 
phosphatidylcholine bilayers induces curvature stress to the membrane thus enabling the fission, 
fusion and budding of membranes [6]. In addition phosphatidylethanolamine and cardiolipin 
participate in accommodation and modulation of membrane proteins and their activities [6, 7]. 
 
The membrane phospholipid composition is strictly controlled both at cellular and tissue levels [8-10]. 
For example, the brain tissue and the retina are enriched in phosphatidylethanolamine and 
phosphatidylserine [11]. Another example is the enrichment of arachidonic acid  (20:4) in the 
phospholipids of pancreatic islets [12]. In addition, the phospholipid acyl chain composition is tailored 
for the purpose of the specific tissue, as in the grey matter where 36% of the fatty acids in 
phosphatidylserine is docosahexaenoic acid (22:6) [3, 12, 13]. This enrichment in 22:6 fatty acid has 
been proposed to be vital for normal development and function of the nervous system [3, 13].  
 
In humans, alterations in lipids are involved in various diseases or pathological processes, such as 
atherosclerosis and type 2 diabetes. Recent advances in lipidomic methods [14] should help to 
understand the role lipids play in these common diseases and may thus allow one in future the design 
of preventive actions. 
  
This work focuses on the metabolism and translocation in mammalian cells of the aminophospholipids 
phosphatidylserine (PS) and phosphatidylethanolamine (PE), which were identified decades ago [3, 7], 
but whose biological functions are still poorly understood.  
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LITERATURE REVIEW 
1. Mammalian Glycerophospholipids 
1.1. Structures and organellar distribution 
1.1.1. General structures 
 
The glycerophospholipids are composed of a polar head group, a phosphate group, a glycerol moiety 
and acyl chains. The phospholipid classes are delineated by the polar head group, while the different 
molecular species are distinguished by their acyl chain compositions (Fig. 1).  
 
 
 
Figure 1. Simplified model of the glycerophospholipid structure – In principle the glycerol and 
phosphate groups are universal building blocks, whereas the polar head group defines the PL class and 
the acyl chains the PL molecular species.  
1.1.2. Molecular species diversity 
 
The phospholipid (PL) molecular species vary in acyl chain length and/or unsaturation. Typically, the 
sn1 position contains a saturated or monounsaturated acyl chain and the sn2 position a mono- or 
polyunsaturated acyl chain [10, 15]. The sn2 acyl chain is ester-linked, while that in the sn1 position 
may be ester-, ether- or vinylether-linked to the glycerol moiety [16]. The acyl chains are commonly 
14- 24 carbons long and contain between 0- 6 double bonds [16].  
1.1.3. Organelle phospholipid composition 
 
Each subcellular organelle has a distinct protein and lipid composition [7]. The plasma membrane 
(PM) is enriched in sphingolipids and sterols [17, 18], while the endoplasmic reticulum (ER) contains 
only low levels of these lipids [17, 18]. The early endosomes resemble the PM in their lipid 
composition, but during their conversion to lysosomes their PS and sterol contents decrease while the 
lysobisphosphatidic acid content increases [19, 20]. The lysosomes resemble the late endosomes with 
a lower PS content compared to the PM [3].  
 
Mitochondria contain only small amounts of PS and trace amounts of sterols and sphingolipids [21], 
while they are enriched in PE. In the rat liver the PE constitutes 20% of the ER phospholipids whereas 
it constitutes 39% and 35% of the inner and outer mitochondrial membrane phospholipids respectively 
[22]. Mitochondria contain 40% of PC, 30% of PE, 10-15% of CL and 5% of PI, PA and PS [22, 23]. 
Mitochondria also contain CL and PG that are not found in other cell organelles [3, 24]. The CL is 
enriched in the inner mitochondrial membrane [3]. Mitochondrial phospholipids also display a distinct 
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acyl chain composition with relatively more of unsaturated (polyunsaturated) acyl chains than in other 
subcellular organelles [24]. 
1.2. Membrane phospholipid asymmetry 
1.2.1. Plasma membrane 
 
The plasma membrane is highly asymmetric. Up to 80% of PE and essentially all of PS is located on 
the  cytoplasmic  leaflet  while  most  of  the  PC  and  SM  is  in  the  exoplasmic  leaflet  [7,  25].  This  
asymmetry is particularly well established in erythrocytes [25]. The bilayer asymmetry relates to 
biological functions such as the various effects of PS externalization, the membrane curvature 
affecting properties of PE and the interactions between plasma membrane embedded proteins with PC, 
SM and sterols. The asymmetry may also contribute to for example cell structure and cell-cell 
interactions [26, 27].  
1.2.2. Endoplasmic reticulum 
 
Phospholipid biosynthesis is mainly conducted on the cytosolic side of the ER thus resulting in the 
necessity for transbilayer movement of the PLs that stay in the ER to maintain leaflet homeostasis 
[28]. For example PE is synthesized on the cytosolic side of the ER and it is rapidly transported to the 
luminal side, with a half time of 20 min [29]. Also, PC and lysophosphatidylcholine are transported. 
The translocation of these PLs is significantly attenuated by protease treatment, but it is not affected 
by addition of ATP [30-32], however, a distinct transporter has not been identified. 
1.2.3. Flippases, floppases and scramblases 
 
Spontaneous transbilayer movement of phospholipids in model membranes is slow. However, in cell 
membranes this movement has been estimated to occur very rapidly, with half times in the order of 
seconds or minutes [33-35]. The rapid transbilayer movement is evidently due to active transbilayer 
transport [36].  
 
The transport  of  PS from the exoplasmic leaflet  to  the cytoplasmic leaflet  of  PM is  mediated by an 
ATP-dependent aminophospholipid translocase referred to as flippase. However, the protein involved 
remains unidentified [7]. The activity of this flippase varies between cell types. Human fibroblasts 
have a one order of magnitude higher aminophospholipid translocase activity than erythrocytes [37]. 
P-type ATPases have been suggested to be responsible for the flippase activity [36, 38]. PS and PE are 
preferred substrates for the ATP-dependent flippases, but PC has also been shown to be transported by 
such proteins [39]. 
 
Flippase activity has been found in e.g. plasma membrane of erythrocytes [34, 38], platelets [38], 
fibroblasts [40, 41], spermatozoa [42], epithelial cells [39] and hepatocytes [43]. Flippase activity has 
also been detected in subcellular organelles such as the Golgi apparatus  [44]. Flippase activity is 
ATP-dependent and sensitive to vanadate and cellular calcium [38, 45]. The transport of spin-labelled 
PS was found to be 10- fold faster than that of PE [34, 38, 46]. Flippase does not discriminate between 
serine enantiomers or between natural PS molecular species [26, 38, 47]. 
 
Lipid transport from the cytoplasmic side to the exoplasmic side of PM is conducted by proteins 
referred to as  floppases.  The transport  is  distinct  from the flippase activity [48].  The floppases seem 
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less specific for the polar head group than the flippases [48]. Floppase activity has been ascribed to be 
(partly) mediated by P-glycoproteins that transport amphiphilic drugs and phospholipids via an ATP 
dependent mechanism [49, 50].  
 
The family of ATP-binding cassette (ABC) proteins has been associated with transbilayer transport of 
phospholipids by functioning as floppases [51]. ABCA1 was suggested to play a key role in apoptotic 
events by promoting transient and local surface exposure of PS in apoptotic cells [52, 53]. However, 
this role has been questioned since there is major scrambling of all phospholipids and not just PS 
during apoptosis [54, 55]. ABCA1 is expressed ubiquitously in human cells [56]. In humans, mutation 
in the ABCA1 protein results in Tangier’s disease [57, 58]. ABCB4 in turn has been located to the bile 
canalicular membranes where it transports PC to the bile [3, 46]. In humans dysfunction of ABCB4 
may result in hepatic cholestasis, while mutation in ABCA4, which is located in the rod and cone 
photoreceptors where it transports retinoids, causes Stargardt’s macular dystrophy [59, 60]. 
 
Scramblases move phospholipids bidrectionally in the PM and thereby “scramble” the phospholipid 
asymmetry [7]. Scramblases have been proposed to be enriched in the so-called lipid rafts [61, 62]. 
The scramblase activity was found in erythrocytes displaying transbilayer movement of phospholipids 
that was ATP-independent and required increased intracellular calcium levels [63]. Scramblases have 
somewhat higher efficiency towards glycerophospholipids than sphingolipids. A protein expressing 
scramblase activity has been purified from human erythrocytes and platelets [64, 65]. However, the 
specific protein that causes the PM phospholipid scrambling has not been identified. Members of the 
scramblase family are found also in the intracellular membranes and the deletion of phospholipid 
scramblase 1 gene in mice did not affect lipid transport [63], thus questioning the role of scramblase 
proteins. Indeed it has been suggested that the increase in Ca2+ concentration itself could promote the 
surface exposure of PS and PM phospholipid scrambling [66]. 
1.3. Interorganelle trafficking 
 
Interorganelle phospholipid translocation is required for distribution of PLs from ER (site of synthesis) 
to other organelles. Lipids do not have intrinsic structures that would direct them to their destination, 
yet the subcellular organelles have distinct membrane lipid compositions [67, 68]. Lipids have a low 
solubility in the aqueous phase suggesting the presence of a distinct transport mechanism since simple 
spontaneous diffusion would be too slow to fulfill the cell’s requirements [69, 70]. Membrane lipid 
compositions and their biophysical properties could further affect the kinetics of lipid transfer, to help 
appropriately direct the lipid transport [71, 72].  
1.3.1. Vesicular transport 
 
Vesicles transporting proteins inside the cell consist of phospholipids. Accordingly, vesicular transport 
of lipids must occur on the routes of protein transport between the Golgi, PM and the ER [63]. Also, 
the endocytotic pathways could participate in lipid translocation from the PM to the subcellular 
organelles [73, 74].  
 
Indeed, nocodazole (a microtubule destabilizing drug) inhibited the transport of fluorescent PC and 
caused accumulation of PC in the endosomes [75]. Also the transport of nascent sphingomyelin from 
the Golgi to the plasma membrane was inhibited by addition of monensin which inhibits protein traffic 
through the Golgi [76]. In addition, arresting vesicle traffic in mitotic cells inhibits the transport of 
sphingomyelin to the PM [77]. 
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1.3.2. Protein-mediated transfer 
 
Arresting vesicle transport by depletion of cellular ATP or reduction of temperature does not abrogate 
the transport of phospholipids from the ER to PM [78-80]. Studies with isolated organelles and 
permeabilized cells have shown that transport of phospholipids occurs even in the absence of the 
cytosolic factors, ATP and GTP [81-83]. Lipid transport also occurs between organelles that do not 
participate in the vesicular pathways including peroxisomes and mitochondria [84, 85]. Non-vesicular 
transport has been shown for PC, PE and PS between ER, mitochondria, the Golgi and the PM [78-80, 
83].  
 
The non-specific lipid transfer protein (nsLTP) has been isolated from the cytosol of human, rat, 
bovine and goat liver and in vitro it has been shown to display broad substrate specificity. The protein 
has been localized to the cytosol and peroxisomes [86, 87]. In mutated CHO cells lacking this specific 
protein the synthesis, transport and decarboxylation of PS was unaltered as compared to normal cells 
[88]. 
 
A protein transporting PI and PC was isolated from bovine brain where it was localized to the Golgi 
membranes [87]. The PI transfer protein has been suggested to be an important component in 
phosphoinositide signal transduction by transporting PI for phosphorylation in the Golgi/PM [89]. 
 
Various proteins have been described to mediate lipid exchange between membrane populations in 
vitro [71, 90]. However, solid evidence for the role of such proteins in vivo is still lacking. It has been 
suggested that the proteins rather might facilitate lipid transfer between membranes and locally 
modulate the lipid composition, thereby regulating vesicle trafficking, signal transduction and lipid 
metabolism [71, 91]. The lipid transfer proteins have been suggested to participate in lipid transfer at 
membrane contact sites, for example the ceramide transfer protein (CERT) that transports ceramide at 
the ER and Golgi contact sites [92, 93].  
1.3.3. Spontaneous diffusion 
 
Several studies have provided evidence for spontaneous movement of lipid monomers, such as the 
transport of newly synthesized PC from its site of synthesis to the PM, which is independent of ATP 
as well as insensitive to disruption of protein traffic through the Golgi (by monensin) and cytoskeletal 
poisons (colchicines and nocodazole) [94-96].  
 
The transport to the PM is also very rapid [78]. The rate of spontaneous movement of PLs between 
membrane compartments is proportional to the lipid’s solubility in aqueous-phase which depends on 
acyl chain length and saturation [95, 97]. Kinetic measurements suggest two types of spontaneous 
translocation [71]. The first type is aqueous diffusion occuring at low membrane concentrations and 
the determining factor is the concentration of the donor membranes, the rate-limiting step being the 
desorption of the lipid from the donor bilayer [71, 95]. The other mechanism depends on membrane 
collisions and that the lipid to be translocated partially extends from the donor membrane thereby 
increasing the propability of transfer when the donor and acceptor membranes collide [98]. This 
mechanism requires high concentrations of both donor and acceptor membranes [69].  
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Figure 2. Mechanisms of phospholipid translocation – PLs may be translocated alternatively via 
vesicles used e.g. for protein transport (A), by phospholipid transport proteins (B), by spontaneous 
diffusion (C) or via organelle contact sites such as those between the MAM and mitochondria (D). 
1.3.4. Contact site –dependent transfer 
 
Phospholipid translocation has been suggested to occur at site of membrane contacts [93, 99]. The 
lipids may by lateral diffusion be transported between membranes at membrane contact sites between 
for example the PM and lipid droplets, ER and mitochondria and lipid droplets and mitochondria [100, 
101].  A membrane contact  site  is  defined as  a  site  with a  very narrow gap (10 -  20nm) between the 
membranes of two organelles enabling traffic of calcium, metabolites and lipids by non-vesicular 
mechanisms [85, 102]. The contact sites are formed and/or stabilized by connection to the apposing 
membrane by protein-protein or protein-lipid interactions. Several proteins implicated in contact site 
formation and stabilization have been identified [103-106]. Examples are the voltage-dependent anion 
channel 1 (VDAC1) that may interact with several ER and mitochondrial proteins [107, 108], and 
STIM1/Orai  which  functions  as  an  ER  Ca2+- sensor [109]. Membrane contact sites may result in 
hemifusion of the apposing membranes and not only enhance their proximities (Fig. 2). 
 
An example of membrane contact sites playing a role in phospholipid transport are those between 
mitochondria and the ER/MAM. MAM have been shown to be in close contact with mitochondria and 
it has been suggested that they mediate the transport of PS [110-112]. The role of MAM in the lipid 
transport has been studied in mnd/mnd mice which have decreased number of ER- mitochondria 
contacts. However, their mitochondrial phospholipid composition was found to be normal [113].  
 
The transport of ceramide between the ER and the Golgi has also been proposed to occur at membrane 
contact sites [114, 115]. In fact the ceramide transfer protein (CERT) has been shown to link the ER 
and the Golgi by binding to the ER and Golgi membranes by the protein’s FFAT motif and PH 
domain [92, 93]. In yeast an ER-mitochondria tethering complex called ERMES has been implicated 
to have a role in determining the mitochondrial CL and PE composition [116]. However, cells with 
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mutated ERMES proteins do not display total inhibition of PL translocation to mitochondria, thus 
suggesting that translocation via ER-mitochondria contact sites is not the only pathway for PL 
transport to mitochondria in yeast [116]. Homologues of ERMES proteins have not been found in 
mammalian cells. However, two proteins, Mitofusin 2 and Mitostatin, have been implicated to 
participate in MAM/mitochondria contact sites [104, 117]. 
2. Aminophospholipids and their functions  
2.1. Signal transduction 
 
Phospholipids have many distinct roles in organisms including intra- and intercellular signalling. 
Some phospholipids serve as precursors for lipid second messengers such as diacylglycerol, inositol-
1,4,5 trisphosphate [7, 118], lysobisphosphatidic acid and arachidonic acid [7], or they can directly 
affect proteins with signalling functions. For example PS has been reported to function as a cofactor or 
activator of protein kinase C, which plays an important role in cellular signalling [119-122]. In 
addition, PS is thought to direct certain proteins to cell membranes [123]. 
 
PE which tends to form cubic phases in vitro [124] affects cellular signalling via its physical properties 
and as a precursor of second messengers. In the PM, PE modulates the membrane curvature and thus 
has a role in membrane fission and fusion [7]. In addition, PE is required at the cleavage furrow in the 
contractile ring assembly during cytokinesis [7]. The ethanolamine moiety from PE is used in 
glycosylphosphatidylinositol anchors of several cell surface signalling proteins [7]. PE also serves as a 
precursor for anandamide [125].  
2.2. Apoptosis  
 
The transbilayer distribution of PS in the PM is connected to its role in apoptosis. PS is externalized 
during the early phases of apoptosis, thus probably serving as a signal for phagocytes [126-128]. It has 
been suggested that macrophages possess a PS binding receptor, but it remains to be identified [129-
132]. PS may be externalized by the putative scramblase (cf. 1.2.3) [133].  
 
The PS molecules that are exposed at the cell surface originate from a pool of newly synthesized PS, 
which may be synthesized by PS synthase 1 or PS synthase 2 [134-136]. It has been shown that neither 
PS synthase is individually responsible for providing the pool of PS that is externalized during 
apoptosis [7, 137]. In addition, a twofold increase in PS synthesis during apoptosis has been reported 
[136, 138].  
2.3. Blood clotting   
 
PS is also tightly connected to blood-clotting, since the exposure of PS at the surface of platelets is 
thought to initiate this event [139, 140]. The externalized PS interacts with proteins of the coagulation 
system [141], leading to an increase in thrombin, which causes conversion of fibrinogen to fibrin and 
subsequently platelet aggregation [139, 142, 143]. High local concentrations of PS are needed for the 
proteolytic activity of the complex consisting of factor VIIa and tissue factor [144]. In addition, 
conversion of prothrombin to thrombin is stimulated by PS and coagulation factor Xa [145]. 
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2.4. Sperm maturation  
 
Externalization of PS has been reported to be part of sperm maturation. It has been proposed to be due 
to decreased inward movement in capacitated cells [146, 147]. The externalization of PS could be 
mediated by an ATP-dependent transporter expressed only in the acrosomal region of sperm [3, 148]. 
This transporter has also been found to be crucial for the normal binding and penetration of the zona 
pellucida of the egg cell. 
2.5. PS surface exposure under pathologic conditions  
 
PS externalization has been connected to several hematologic pathologies. In Scott syndrome, the 
platelets function normally, but have impaired scramblase activity, leading to impaired externalization 
of PS [149]. In antiphospholipid syndrome circulating antiphospholipid antibodies seem to target 
plasma proteins interacting especially with PS resulting in e.g. arterial and venous thrombosis [150-
152]. In sickle cell anemia, a subpopulation of cells is lacking detectable aminophospholipid 
translocase activity and displays a partial collapse of membrane phospholipid asymmetry including 
surface exposure of PS [153-155]. In thalassemia, which causes congenital hemolytic anemia, the 
complications might be due to the procoagulant effect of a PS-exposing subpopulation of erythrocytes 
[152, 156].  
 
In approximately 3% of uremic patients a subpopulation of erythrocytes express PS at their surfaces 
[157]. Uremic patients undergoing repeated peritoneal dialysis have less erythrocytes expressing PS 
and less severe anaemia [152, 157]. The exposure of PS is also connected to kidney stone disease 
[158, 159]. In diabetes mellitus erythrocytes and platelets show partial collapse of membrane 
phospholipid asymmetry as well as exposure of PS [152, 160].  
 
Infected cells express PS when going to apoptosis and it has been found that several virus-infected 
cells exhibit a procoagulant phenotype [152, 161]. Also bacterial infections cause exposure of PS in 
the  cells,  an  example  of  such  bacteria  is  Chlamydia pneumonie that  has  also  been  found  in  
atherosclerotic lesions [152, 162]. A significant increase in PS exposure has also been reported in 
tumorigenic vs. nontumorigenic cells [152, 163, 164].  
3. Metabolism of Aminophospholipids  
3.1. Phosphatidylserine  
3.1.1. Biosynthesis  
 
Mammalian  cells  contain  two  known  PS  synthetases,  PSS1  and  PSS2,  which  use  PC  or  PE,  
respectively, as substrates in a base-exchange reaction (Fig. 3) [165]. It has been proposed that there is 
a third an ER-specific enzyme that would explain the PS synthesis activity in ER [3, 135]. PS 
synthesis occurs in the ER with the highest specific activity in MAM [112, 135, 166]. The synthesis 
itself is not dependent on energy but a sufficient Ca2+ concentration is required [7, 83, 167].  
 
In vitro, PSS1 utilizes both PC and PE as substrates [3]. The PE and PC consumed in the reaction can 
be replenished by the Kennedy pathway, which can incorporate the released choline or ethanolamine 
back to PC and PE [168]. The two PSS proteins are predicted to have several membrane spanning 
domains and the amino acid sequences are 30% identical [165, 169, 170].  
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The two PS synthases are encoded by different genes [171, 172]. The PSS1 gene has been localized to 
chromosome 13 in the mouse and to chromosome 8 in humans [3, 173]. The relative expression levels 
of the two PS synthases vary between tissues suggesting that they could have specific functions [7]. 
The PSS1 mRNA is expressed ubiquitously in mouse tissues and especially abundant in liver, kidney 
and brain tissues. The PSS2 mRNA is mostly expressed in Sertoli cells of the testis and at significantly 
lower levels in the heart and brain. In the brain PSS2 is expressed especially in the Purkinje cells of 
the cerebellum and the pyramidal neurons of the hippocampus [173-175].  
 
Mice models deficient in either PSS1 or PSS2 have been generated [7, 174]. The PSS1 knock-out mice 
showed no obvious phenotype and both genders were fertile [7]. The PSS2 -/- females were fertile, but 
the males displayed smaller testes than normal and approximately 10% of them were infertile with 
atrophied testes and spermatic ducts lacking spermatocytes, hyperplasia of Leydig cells and an 
abnormally thick layer of Sertoli cells [174]. In contrast to the single knock-out mice the double 
knock-out are not viable [176].  
3.1.2. Regulation of PS synthesis  
  
The regulation of PS synthesis is a key issue in cellular PS homeostasis. The synthesis is regulated by 
the cellular PS level [177]. However, only little is known about the transcriptional regulatory 
mechanisms of the expression of the PSS genes [7]. 
 
The contribution of the two PSS enzymes to PS synthesis was studied using CHO cells deficient in 
PSS1. These cells displayed a 35-55% lower PS-synthesis than normal cells and decreased amounts of 
PS and PE [171, 172]. In addition, their growth was severely impaired if not supplemented with PS, 
PE or ethanolamine [171, 172]. The PS synthesis activity was lowered by 95% as compared to 
parental cells when PSS1 deficient CHO cells were further mutagenized resulting in an 80% decrease 
of PSS2 mRNA. These cells were viable only when supplemented with PS [170, 178]. Overexpression 
of PSS2 eliminated the need for PS supplementation in PSS1 deficient CHO cells [175] indicating that 
there is no intrinsic need for PSS1 in CHO cells [7].  
 
In rat brain, phosphorylation of PSS1 was suggested to regulate the synthesis of PS [179]. There are 
also implications that the synthesis is regulated by the need for distinct PS species since synthesis by 
PSS1 in brain and liver microsomes prefers PC species containing docosahexaenoic acid as substrates 
[13]. In CHO cells, increased cellular PS level resulted in reduced rates of incorporation of radiolabel 
into PS [177]. In addition, the activity of PSS2 purified to near homogeneity, was inhibited by addition 
of PS but not PE or PC [180] , indicating that PSS2 is inhibited by direct interaction with PS [180, 
181]. Inhibition of PS synthesis by exogenous PS was absent in a CHO mutant (mutant 29) [182]. It 
was found that a point mutation in the PSS1 gene was behind the aberrant regulation of PSS activity 
[183]. In this mutation Arg-95 is changed to lysine causing the resistance to end product inhibition of 
the synthesis. Similarly, in PSS2 an arginine residue is located at position 97 and changing this residue 
to lysine results in a 4- fold higher PS synthesis compared to parental CHO-K1 cells [181]. 
 
When PSS1 was overexpressed in McArdle 7777 rat hepatoma cells, incorporation of 3H-serine into 
PS was increased 3-fold, but the cellular levels of PS or PE did not increase [184], possibly due to an 
increase in the PSD pathway and a decrease in the CDP-ethanolamine pathway of PE synthesis [184]. 
In contrast, the equivalent overexpression of PSS2 did not increase the incorporation of 3H-serine into 
PS [175]. However, overexpression of PSS2 in CHO cells increased the ethanolamine-exchange 
activity by 10-fold, whereas the choline-exchange activity was unaffected as expected [178] indicating 
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that PSS2 is responsible for the ethanolamine exchange activity. These data implicate tight regulation 
of PS synthesis activity in order to maintain optimum levels of PS [7]. 
 
PSS2 -/- mice do not have severe developmental abnormalities or changes in PL composition [174].The 
hepatocytes of PSS2 -/- mice had normal levels of PS and PE, possibly due to increased PSS1 activity 
and decreased PS degradation, but not due to increased PSS1 mRNA levels [185].  
 
 
Figure 3. Synthesis of PS and PE – PS is synthesized by a base-exchange reaction with the highest 
activity  in  the  MAM  by  either  PS  synthase  1  or  PS  synthase  2.  PE  on  the  other  hand  may  be  
synthesized in ER/MAM de novo by  the  Kennedy  pathway,  which  is  similar  to  that  of  PC,  or  via  
decarboxylation of PS, by PS decarboxylase (PSD) in the mitochondria. 
3.2. Phosphatidylethanolamine  
3.2.1. Biosynthesis 
 
PE is synthesized via two alternative pathways, the CDP-ethanolamine (Kennedy) pathway [186] and 
the PS decarboxylation pathway (Fig. 3) [168]. In mammals the precursor, ethanolamine, is mainly 
obtained from the diet or from degradation of PE derived from PS. In addition small amounts of 
ethanolamine are generated upon degradation of sphingolipids [187].  
 
The first reaction in the Kennedy pathway is catalyzed by ethanolamine kinase [188]. Two different 
isoforms of this enzyme exist. One, EK2, is able to phosphorylate both ethanolamine and choline, 
whereas another, EKI1 can only phosphorylate ethanolamine [188, 189]. The second step, often 
considered as the rate-limiting one, is catalyzed by CTP-ethanolamine cytidylyltransferase. The third 
and final step, i.e. reaction of CDP- EA with diacylglycerol, is catalalyzed by the CDP-ethanolamine 
diacylglycerol ethanolaminephosphotransferase [190, 191]. 
 
Only one gene encoding CTP-ethanolamine cytidylyltransferase has been identified in eukaryotes [7]. 
The mRNA encoding choline/ethanolamine phosphotransferase has been shown to be ubiquitously 
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present in different human tissues. The enzymatic activity is found primarily in the ER [166, 190, 
192].  
 
The PS decarboxylase, first discovered in bacteria [193], contributes to the majority (up to 80%) of the 
PE pool even when ethanolamine is included in the cell culture media in BHK and CHO cells [168, 
194, 195], while in rat hepatocytes and hamster heart most of the PE is derived from the Kennedy 
pathway [7, 196]. In CHO cells, the CDP-ethanolamine pathway mainly produces molecules with 
mono- or diunsaturated acyl chains at the sn2 position, whereas the PSD pathway preferentially 
produces species with polyunsaturated acyl chains at this position [197]. PSD may act selectively on 
PS species with different acyl chains, however this has not been convincingly proved [197-200]. 
 
In mammalian cells PS decarboxylase is found only in the inner mitochondrial membrane [201, 202] 
with its active site facing the intermembrane space [7, 200, 202]. The cDNA encoding the PS 
decarboxylase was identified in complementation experiments with CHO cells defective in PS 
decarboxylase activity [203]. The PSD protein consists of 409 amino acids [204] and the amino 
terminus of the protein contains regions that target proteins to the mitochondria which thus explains its 
localization [204, 205]. The complete processing of the PS decarboxylase in mammalian cells is 
shown to occur in three proteolytic steps completed during localization to mitochondria [200, 204].  
3.2.2. Regulation of PE synthesis 
 
The regulation of the CDP-ethanolamine pathway is not known well. The major regulatory step is 
presumably the reaction catalyzed by the CTP-ethanolamine cytidylyltransferase [196, 206], albeit 
under certain conditions, the preceeding step, catalyzed by the ethanolamine kinase, may be rate-
limiting [188]. Mice lacking the ethanolamine-specific kinase have increased perinatal mortality, but 
have normal liver PE content [207], probably because choline/ethanolamine kinase can compensate 
for the defect [7]. 
 
The reason for the existence of the PSD pathway in mammals is not well understood, but it could be 
necessary to provide adequate amounts of PE to the mitochondrial membranes [208, 209]. PS 
subjected to decarboxylation has been suggested to originate from a pool of newly synthesized PS [81, 
82, 112] and there is evidence that the PE formed by decarboxylation does not readily mix with the PE 
already present in the inner mitochondrial membrane [210]. PSD deficient mice do not survive past the 
ninth embryonic day. This strongly suggests that the PSD pathway is essential for development [209]. 
Fibroblasts of the PSD -/- mice display fragmented and aberrantly shaped mitochondria implicating 
that the reduced mitochondrial PE lies behind the observed defects and the embryonic lethality. The 
PSD +/- mice, on the contrary, appear normal and display normal mitochondria and PE content in the 
liver and other tissues. In the heterozygous mice the activity and amount of the CTP-
phosphoethanolamine cytidylyltransferase was found to be increased implicating increased synthesis 
of PE via this pathway possibly compensating for the PSD deficiency [209].  
 
Both  pathways  for  synthesis  of  PE,  i.e.  the  PSD  and  the  CDP-ethanolamine  pathways,  seem  to  be  
essential for normal mouse development since also Pcyt2 -/- (the gene encoding the CTP- 
phosphoethanolamine cytidylyltransferase), mice are embryonic lethal in addition to PSD -/- mice [7]. 
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3.3. Remodelling of (PS and PE) phospholipids 
 
Theoretically, all phospholipid molecules present in the cell could be synthesized directly de novo. 
However,  in  most  cells  many of  the species  are  formed via  remodelling,  i.e.  one or  both of  the acyl  
chains are exchanged for others [211]. The sn2 position is more often remodelled than the sn1 one 
[212]. The remodelling requires a sequential action of A-type phospholipases (PLAs) cleaving either 
sn1 or sn2 chain, and a recacylating enzyme [15, 213, 214]. The remodelling process may also include 
transfer  of  a  fatty  acid  from one  PL  to  another  in  a  process  referred  to  as  transacylation  [215].  For  
example, arachidonic acid can be first incorporated in PC by acyl-CoA-lysophoshatidylcholine 
acyltransferase (LPCAT) [215] and is then transferred from PC to lyso-PE by CoA-independent 
transacylase (CoA-IT). The PLA2 enzymes, especially the iPLA2 enzymes, play an important role by 
providing a stable pool of lysophospholipids as acyl chain acceptors [216-218]. 
3.3.1. Phospholipases 
 
Two types of PLAs are involved in the remodelling of phospholipids, namely the PLA1s and PLA2s 
cleaving the sn1 or sn2 acyl chain, respectively.  
 
The  PLAs  targeting  the  sn1 linkage (PLA1) are poorly known. PLA1 activity has been detected in 
fungi, bonito muscle, bovine brain and testis, hornet venom and rat platelets [219]. The PLA1s mostly 
target PC molecular species, but the PLA1s found in rat platelets and bovine testis target PS and PA, 
respectively [220, 221]. 
 
Numerous different proteins with PLA2 activity have been recognized [222, 223] and can principally 
be divided into five groups; sPLA2s, cPLA2s, iPLA2s, PAF acetylhydrolases and lysosomal PLA2s 
[213, 223]. sPLA2s are secreted poteins and require Ca2+ for catalysis [223]. sPLAs have been found 
in various sources including snake and scorpion venoms, pancreatic juices, arthritic synovial fluid and 
several mammalian tissues [213]. The mammalian sPLA2s do not show preference regarding the acyl 
chains, but may have some head group specificity [213]. Typically sPLA2s possess high activity 
towards anionic phospholipids [224].  
  
cPLA2s are large cytosolic proteins and the first member found of this group (GIVA PLA2) required 
calcium for translocation to a membrane [225-227]. The cPLA2s have been implicated in acyl chain 
turnover of phospholipids in cells stimulated via surface receptors. The cPLA2 members differ from 
each other in regard to their regulation by calcium [228-231]. GIVA PLA2 is the only PLA2 that 
exhibits a clear preference towards AA in the sn2 position [232, 233]. It has also lysophospholipase as 
well as transacylase activities [232-234]. Its activity is regulated by calcium which makes the enzyme 
bind to a membrane via its C2 domain thereby stimulating its activity [235-239]. The GIVB and GIVC 
PLA2s have only modest specificity for the sn2 acyl chain [230, 240]. GIVD, -E and F cleave AA and 
linoleic acid with equal efficiency and GIVF prefers PE over PC [228]. 
 
The enzymes of the iPLA2/GVI group do not require Ca2+ for their activities. The GVIA1 (iPLA2?) is 
in the cytosol, but upon stimulation translocates to the nucleus, ER, Golgi and mitochondria [241]. 
GVIB PLA2 (iPLA2?) has been localized to the ER, mitochondria and the peroxisomes [242, 243]. 
The role of GVIA1 and GVIA2 in mammalian phospholipid homeostasis is dependent on the cell type 
[244-247]. GVIA was originally purified from macrophages and subsequently from several different 
sources [248-250]. This enzyme is in addition expressed as multiple splice variants, thereby increasing 
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the complexity of the GVIA PLA2 family [251]. Four other members of the GVI group have been 
recently found, i.e. neuropathy target esterase (GVIC), adiponutrin/PNPLA3 (GVID), TTS-2.2 (GVIE) 
and GS2 (GVIF) [252, 253]. 
 
The enzymes of the GVI group (mainly GVIA1 and GVIA2) produce free AA, lysophospholipids and 
lyso-PA and have transacylase and lysophospholipase activity [216, 223, 254]. They seem also to 
participate in phospholipid remodelling and PC homeostasis [216, 255]. However, studies in INS-1 
cells, a model for pancreatic islet ?- cells secreting insulin, have suggested that GVI PLA2 enzymes 
are more important in cell signalling than in remodelling of phospholipids [255, 256].  
 
The PAF acetylhydrolases are divided into two groups, i.e. GVII and GVIII, and both of them 
hydrolyze the sn2 acyl chain of PAF. PAF acetyl hydrolase GVIIA cleaves acyl chains up to 9 carbons 
long from the sn2 position of oxidized lipids [213]. The PLA2 activity has been shown to decrease 
with increasing chain length of the sn1 acyl chain [257]. The GVIIA is the only PLA2 that has been 
shown to be able to operate in the aqueous phase [257, 258].  
 
 
Figure 4. Routes for phospholipid remodelling – Phospholipid remodelling is a coordinated action of 
phospholipase and acyltransferase/transacylase activities. Simplified, either the sn1 or sn2 position 
acyl  chain is  cleaved off  by a  PLA1/PLA2, respectively.  Thereafter  a  new acyl  chain is  attached by 
acyltransferase activity. 
 
The fifth group consists of one enzyme, 1-O-acylceramide synthase (ACS), it has been purified from 
bovine brain. It esterifies the C-1 position of ceramide by acyl chains derived from phospholipids 
[259]. The ACS possesses both PLA2 and transacylase activities [260]. ACS enzyme has been shown 
to preferentially hydrolyze PC and PE species [259]. 
3.3.2. Acyl transferases 
 
Acyl chain remodelling of phospholipids requires hydrolysis by a PLA and subsequent reacylation by 
an acyl transferase (Fig. 4). The exchange of acyl chains may also be mediated by a transacylase. 
While only few transacylases are known, several acyltransferases are involved in remodelling. The 
acyltransferases are divided into several groups according to their (primary) lysophospholipid 
acceptor, e.g. LCLAT (lyso-cardiolipin acyl transferase).  
 
Acyltransferases possibly involved in phospholipid, PE and PS, remodelling are LPCAT3, LPCAT4, 
LPEAT1. All three possess LPEAT activity while the latter two also have LPSAT activity. In addition 
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the LPCAT3 and 4 display LPCAT activity [261, 262]. The LPCAT3 shows a preference for 
polyunsaturated acyl chains and 18:2-CoA whereas the LPCAT4 and LPEAT1 prefer the 18:1-CoA.  
 
LPCAT1 catalyzes the synthesis of dipalmitoyl-PC and exhibits LPGAT activity [263, 264]. It is 
mostly expressed in the lung tissue [264]. In addition to LPCAT and LPGAT activity the enzyme has 
been shown to also catalyze PAF synthesis with a preference for 18:2- and 18:3-CoAs [263, 264]. 
LPCAT2 possesses LPCAT activity with a preference towards 20:4-CoA, but it is primarily involved 
in PAF biosynthesis and remodelling [265]. LPIAT1 has only been shown to catalyze the 
incorporation of AA and eicosapentaenoic acid to lysoPI [10]. 
4. Intracellular trafficking of aminophospholipids  
4.1. Phosphatidylserine 
 
Transport of PS (NBD-PS) from the PM to subcellular organelles is not vesicle-mediated since it was 
rapidly and extensively transported into subcellular organelles even when the temperature was lowered 
to 7 °C [40]. Translocation of labelled PS to mitochondria can be followed by monitoring formation of 
labelled PE since in mammalian cells PS decarboxylase is found only in the mitochondria and because 
that transport rather than decarboxylation proper is the rate-limiting step [81, 82]. Translocation of 
pyrene-labelled PS molecular species has been studied in BHK cells and was found to be dependent on 
the hydrophobicity of the PS molecular species, i.e. the more hydrophobic species are translocated 
more slowly, suggesting that the transport is due to spontaneous diffusion [266]. However, addition of 
a partially purified calcium-binding protein, S100B, to permeabilized CHO-K1 cells enhanced 
translocation of PS to mitochondria presumably due to an increased number of contact sites between 
MAM and the mitochondria [267]. 
 
Transport of PS from ER to mitochondria has been shown to be independent of cytosolic proteins in 
permeabilized CHO-K1 cells [81-83]. However, transport of PS to mitochondria was inhibited by 
depletion of ATP and cycloheximide poisoning [268]. ATP dependence of the transport process has 
been shown in experiments with permeabilized cells showing that the ATP required for transport is not 
connected to the ATP related to PS synthesis [81-83]. ATP may be required for the release of PS from 
the MAM fraction and therefore needed in the transport process [83, 208]. Depletion of cellular ATP 
caused accumulation of PS into the near vicinity of the mitochondria and also inhibition of PS 
decarboxylation [208]. However, in in vitro experiments with purified mitochondria and liposomal 
donors or isolated microsomes the transport and subsequent decarboxylation was independent of ATP 
[81, 82]. 
 
It has been estimated that in HeLa cells ~20% of the mitochondrial surface would be in contact with 
the ER [269]. Co-isolation of MAM with mitochondria from rodent livers has implicated that there is 
an association between these organelles [112, 270]. Indeed, morphological studies have revealed sites 
of close apposition or contact sites [269, 271]. One of the proteins suggested to maintain these MAM-
mitochondria contact sites is Mitofusin 2 which has been shown to be required for calcium uptake into 
mitochondria [104]. Contact sites may also be involved in the transport of PS between the outer and 
inner mitochondrial membranes [210, 272, 273]. It has been proposed that transport of PS from MAM 
to mitochondria is assisted by close proximity or contacts between these organelles [112, 270]. 
Subcellular fractionation of CHO cells labelled with 3H-serine  revealed  that  the  labelled  PS  was  
located both in the ER and MAM prior to decarboxylation and that it after depletion of ATP 
accumulated in MAM [208].  
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The role of the contact sites in PS transport is supported by that trypsin treatment of mitochondria, i.e. 
reduction of MAM-mitochondria contacts, as well as reduction of contacts between the outer and inner 
mitochondrial membranes by dinitrophenol, inhibit transfer and subsequent decarboxylation of PS 
[111, 274]. However, results from experiments with proteinase treatment of mitochondria with either 
trypsin or proteinase K have been inconsistent since in some studies either significant or no effect on 
uptake and decarboxylation of PS has been observed [3, 81]. Mutant CHO-K1 cells, which have 
normal PS synthesis and functional PSD, but defective decarboxylation have been found [275]. This 
deficiency appears to be due to a lesion in transport of PS from OMM to IMM, but the details of the 
defect remain unidentified [275]. 
 
 
 
Figure 5. Theoretical translocation routes for PS (A) and PE (B) – PS may be transported from the 
PM directly to the mitochondria (1) or via ER (2) to mitochondria (3) for subsequent decarboxylation. 
Newly synthesized PS is translocated from the ER to mitochondria (3) or to other cell compartments 
such as the PM (4). PE is transported from mitochondria to the ER (1) and other cellular compartments 
(2) or alternatively from the ER to the PM (3) or in small amounts to mitochondria (4). 
4.2. Phosphatidylethanolamine 
 
PE is synthesized in mitochondria and ER, and is yet present in all membranes. Thus PE must be 
translocated from these organelles to others. PE, similarly to PC, has been shown to be transported 
from its site of synthesis (mainly the ER) to the PM, even in absence of ATP [78, 79]. Cells labelled 
with 3H-ethanolamine showed that newly synthesized PE is transported to the PM without a detectable 
lag and that in pulse-chase experiments the transport continued for up to 2 h [79]. Transport of newly 
synthesized PE is kinetically very similar to that of PC, i.e. it is rapidly transported to the PM [79]. In 
contrast to the transport to the PM, the transport from microsomes to the mitochondria was found to be 
up to 80- fold slower for PE than for PC [276]. Transport experiments with isolated microsomes and 
mitochondria from rat liver tissue displayed a sequential transfer of PE from microsomes first to the 
outer and then to the inner mitochondrial membrane [277-279]. In CHO cells labelled with 3H- 
ethanolamine, the resulting PE specific radioactivity was 10 times lower in mitochondria than in the 
microsomes after 2 h and practically no radioactivity was seen in the inner mitochondrial membranes 
[208]. Similarly, when mitochondria were exposed to trinitrobenzene or when the outer mitochondrial 
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membrane was removed with digitonin the imported PE was found primarily in the outer 
mitochondrial membrane [280].  
 
PS derived PE may constitute up to 80% of the total cellular PE pool which indicates translocation 
from mitochondria to other cellular compartments [210]. The translocation of PE from the inner to the 
outer mitochondrial membrane has been shown to occur rapidly [274]. However, PE formed in 
mitochondria is suggested to be essential for the function of the organelle [208, 209].  
 
In addition, there is clear evidence that the PE produced in mitochondria is transported to ER and PM 
[80, 208]. Transport of PE from mitochondria to PM in rat hepatocytes does not seem to be vesicle-
mediated, since it is not inhibited by the disruption of the Golgi by Brefeldin A, but the detailed 
mechanism is not known [80]. Transport of the mitochondrial PE to the PM is very rapid and exceeds 
that of PE synthesized in the ER [80].   
5. Tools to study metabolism and intracellular trafficking of phospholipids 
5.1. Radiolabelled precursors 
 
In order to study metabolism of newly synthesized phospholipids, labelled precursors have to be 
employed. Traditionally phospholipid synthesis and turnover has been investigated using radiolabelled 
precursors (e.g. 3H-serine or 14C-ethanolamine) [208, 268].  However, the use of radiolabelled 
precursors is problematic when studying individual phospholipids molecular species, since one has to 
separate the species by HPLC and determine the radioactivity and phosphate content of each fraction, 
which is laborious and insensitive. 
5.2. Stable isotope-labelled phospholipids 
 
The most recent advance in studies of phospholipids has been the synthesis of isotope-labelled 
phospholipids. The isotope labels, usually deuterium, may be located in the polar head group, in the 
acyl chains of the lipid in question or in both positions simultaneously. These phospholipids are 
chemically and physically nearly identical to endogenous phospholipids, since the only difference is 
the number of neutrons present in H or C. The isotope label is also an effective way to separate 
endogenous and labelled species by mass spectrometry, thus providing detailed data. 
 
The combination of labelled precursors and mass spectrometric methods has been used for example to 
study the composition and dynamic remodelling of endonuclear glycerophospholipids in cultured cells 
[281]. By using isotope-labelled precursors pre-existing and newly synthesized PCs could be 
distinguished by alternative precursor ion scans [282]. In addition isotope-labelled methionine, that 
incorporates into PE by methylation, has been used to study the translocation of PC between ER and 
mitochondria in yeast [283], while isotope-labelled ethanolamine and choline have been used to study 
PE and PC metabolism in rat hepatocytes [284].  
 
It is also possible to introduce the label in acyl chain moieties. This allows one to follow incorporation 
of a distinct acyl chain into subcellular organelles as well as to study phospholipid remodelling. The 
remodelling process has been studied for example in the synthesis of lung surfactant and PC synthesis 
in the liver tissue [285-287].  
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5.3. Fluorescent and spin-labelled lipid analogs 
 
Fluorescent analogues of phospho- and sphingolipids have provided useful information on lipid 
translocation in both cytological and biochemical studies [68]. In addition the NBD-analogues of PC, 
PE, PS, PI, PA, SM, glucosylceramide and ceramide have been used to study lipid transport in cells 
[40, 75, 288-291]. Spin-labelled phospholipids have also been used for lipid transbilayer transport 
studies [29, 292]. The fluorescent analogs provide means to visually follow e.g. translocation of PLs. 
However, both the NBD- and BODIPY labelled analogues are more hydrophilic than the 
corresponding endogenous PLs thus resulting in data that does not fully correspond to the “natural” 
conditions [293, 294]. Pyrene-labelled phospholipid analogues resemble their natural counterparts 
more closely than NBD- and BODIPY-analogues [295], but also they carry an unnatural group that 
may cause aberrant behaviour. 
5.4. Carriers of exogenous phospholipids 
 
Labelling cells with phospholipids with very short acyl chains (i.e. low hydrophobicity) does not 
require additional carriers for effective transfer into cells. However, short-chain phospholipids 
spontaneously translocate between intracellular organelles and can be rapidly degraded. 
Lysophospholipids rapidly translocate to cells and are subsequently acylated therein, but the acylation 
produces multiple molecular species, thus complicating data interpretation.  
 
Phospholipids which are equally hydrophobic as the endogenous ones do not spontaneously transfer to 
cells and thus carriers are needed. In principle the most delicate approach is to use lipid transfer 
proteins, but impractically high amounts of the protein are required for adequate labelling [296, 297]. 
Also other approaches, such as cells labelled with lipid vesicles containing a viral receptor have been 
used, but these turned out to be impractical due to complications [298].  
 
Cyclodextrins are cyclic oligosaccharides with a hydrophobic cavity and can carry cholesterol and 
phospholipids [299-301]. Certain cyclodextrins transfer even efficiently hydrophobic phospholipids, 
thus making them potential carriers when introducing exogenous phospholipids to cells [266, 294, 
302]. However, cyclodextrins can deplete cholesterol from cells and thus compromise their viability.
  
5.5. Monitoring of interorganelle translocation 
 
Intracellular translocation of phospholipids may be studied by labelling cells with fluorescent 
phospholipid analogues and subsequently following the distribution of fluorescence in subcellular 
compartments. However, the fluorescent analogues do not fully behave as the corresponding 
endogenous PLs. Alternatively, one can exploit site-specific reactions, such as PS decarboxylation to 
study interorganelle translocation of PLs [303] or conduct subcellular fractionation [87, 208]. 
5.5.1. Subcellular fractionation 
 
Intracellular transport of phospholipids may be studied by metabolic labelling of PLs combined with 
subcellular fractionation [87, 208]. However, impurity of the separated organelles is a major problem. 
For example endosomes (50% yield) with only a 5% contamination by ER membranes can contain up 
to 50% of ER derived lipids due to the 10-fold greater abundance of ER membranes [304]. The purity 
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of fractions may be increased by including additional steps, but this reduces the yield and increases the 
risk of losing subfractions of the organelle [14]. 
 
The crude mitochondrial fraction obtained by differential centrifugation is contaminated by lysosomes 
and the ER membranes (MAM). MAM may be removed by centrifugation in a Percoll density gradient 
[305, 306] or by protease treatment disrupting contact sites between mitochondria and MAM [111, 
307, 308]. The mitochondria can be further subfractionated to the outer and inner mitochondrial 
membranes by digitonin treatment followed by centrifugation [274, 309].  
5.5.2. Site-specific modifications  
 
In  mammalian  cells  formation  of  PE  from  PS  can  be  used  to  follow  the  transport  of  PS  to  
mitochondria, since the PS decarboxylase is located explicitly in the inner mitochondrial membrane 
and since transport is the rate-limiting step rather than decarboxylation proper [166, 202, 310].  
 
Transport of PS derived PE from mitochondria to the ER may be followed by methylation of PE to 
corresponding PC by the PEMT located in the ER, with the bulk activity localized to the MAM [112, 
311]. However, this approach can be used only in cells that express PEMT activity, such as 
hepatocytes or PEMT overexpressing cells [112, 311]. 
5.6. Elucidation of the phospholipases involved in PL metabolism 
5.6.1. Pharmacological inhibitors 
 
The function of individual PLA2 proteins involved in phospholipid metabolism has been studied 
extensively by using pharmacological inhibitors that act specifically on the different PLA2 proteins 
[312, 313].  
 
Commonly used inhibitors of GIVA PLA2 (cPLA2?) are arachidonyl trifluoromethylketone (ATFK), 
pyrrophenone and methyl arachidonyl fluorophosphonate (MAFP). Neither ATFK nor MAFP are 
100% specific thus complicating data interpretation [314-316]. The most potent inhibitor of GIVA 
PLA2 is pyrrophenone [317, 318].  
 
Bromoenollactone (BEL) is the most commonly used inhibitor of iPLA2. The S- and R-enantiomers of 
BEL display partial specificity towards iPLA2? (GVIA) and iPLA2? (GVIB), respectively [319]. 
However, BEL is not fully specific for iPLA2, but inhibits also e.g. PA phosphatase [320, 321]. 
5.6.2. RNA interference 
 
The most attractive method available for inhibition of phospholipases is RNA interference. siRNA (or 
anti-sense oligonucleotides) have been used to knock-down GVIA PLA2, GVIB PLA2, GIVA PLA2, 
GIII PLA2, GX PLA2 and GVIII PLA2 [216, 322-326]. In addition, knock-out mice models may be 
generated as done for example for GVIA PLA2 [327, 328]. 
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5.7. Mass spectrometry 
 
Mass spectrometric lipidomic methods have developed rapidly in recent years. Combining stable-
isotope labelling with mass spectrometry has added an important dimension to lipidomics [284, 329, 
330]. 
 
There are two principal ways to conduct mass spectrometric analysis of lipids, i.e. tandem-MS or LC-
MS (see below). For ion separation various analyzers may be used [331], ion-traps  for full scan mode, 
i.e. scan for a range of masses (m/z), and quadrupole analyzers for multiple reaction monitoring [215, 
329, 332]. The analyzers filter the ions based on their m/z (mass-to-charge-ratio) by adjusting the 
electrical field by DC (direct current) and RF (radio frequency) potentials of the analyzers [331]. 
 
The data obtained from mass spectrometry needs to be further analyzed. Internal standards should be 
included in samples for enabling quantitative analysis, and for the analysis itself specific software 
have been developed that take into account factors such as variations in ionization efficiency and 
deisotoping effects [333-336].   
5.7.1. Direct infusion (DI) and class-specific scanning 
 
Direct infusion combined with class-specific scanning (neutral loss or precursor-ion scanning) enables 
detection of different lipid classes and species with high sensitivity and specificity [337, 338]. The 
precursor ion scanning is achieved by direct infusion with subsequent scanning of characteristic ions 
acquired by fragmentation (ESI-MS/MS) [338-340]. The first quadrupole of a triple quadrupole scans 
for a range of m/z for glycerophospholipids, the second chamber then fragments the ions, selected in 
the first one, by collision-induced dissociation (CID). Finally the third quadrupole transmits a 
fragment with a specific m/z so that only ions producing the specific fragment are detected [341, 342]. 
For  example,  PC  species  can  be  detected  by  scanning  for  the  precursor  with  a  m/z of 184 
(phosphocholine) [343, 344]. PS and PE can be detected by scanning for neutral loss of 87 or 141, 
respectively. 
 
Compared to LC-MS, direct infusion has the advantage of constant electrospray conditions, but 
isobaric species may not be quantified without subsequent fragmentation. In addition, the sensitivity is 
not adequate for quantification of minor species [345]. 
5.7.2. Liquid chromatography- mass spectrometry (LC-MS)  
 
Combination of normal phase liquid chromatography (LC) with masspectrometry offers an alternative 
way of analyzing phospholipids. In normal phase LC the phospholipids are separated by their head 
groups, i.e. the PL classes are eluated at different times, while the reverse phase LC separates 
molecular species by their acyl chain residues [334, 346]. Triple quadrupole analyzers, in the context 
of LC-MS, also allow sensitive monitoring called MRM (multiple reaction monitoring). LC-MS is 
more sensitive than direct infusion since the impurities that might cause suppression are separated. 
However,  use  of  LC-MS  increases  the  time  needed  for  analysis  as  well  as  complicates  the  
quantification due to changes in eluent composition which in turn affect the ionization efficiency 
[347]. 
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DI-MS/MS and LC-MS allow the detection of both labelled and unlabelled lipids selectively [284, 
337, 338]. Several stable-isotope labelled precursors may be used simultaneously using head group 
specific scanning. For example synthesis of D4-PE  and  D9-PC may be studied simultaneously by 
labelling with D4-ethanolamine and D9-choline and applying specific head group scans, neutral loss of 
145 and precursor ion scan of 193, respectively [348].  
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AIMS OF THE CURRENT STUDY 
 
The main goal of the current study was to elucidate factors contributing to aminophospholipid 
remodelling and intracellular translocation in mammalian cells. More specifically, we studied: 
 
- Introduction of intact stable-isotope labelled phospholipids to cultured cells using cyclodextrin 
as a carrier. 
- Pathways and kinetics of remodelling of exogenous phospholipid species in cultured cells and 
the A-type phospholipases involved in this process. 
- Import of phosphatidylserine and -ethanolamine to mitochondria and export of 
phosphatidylserine-derived phosphatidylethanolamine from mitochondria. 
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EXPERIMENTAL PROCEDURES 
 
Lipids and reagents – The unlabelled lipids and cholesterol were obtained from Avanti Polar 
Lipids (Alabaster, AL). The PE and PS species with a deuterium-labelled head group were synthesized 
from corresponding PC species and D-ethanolamine or D-serine by using phospholipase D mediated 
transphosphatidylation [349], except with a five-fold reduced reaction volume. The deuterium-labelled 
PC species were synthesized from corresponding PE species by methylation with D-methyl iodide 
[350]. The products were purified by normal phase HPLC [351], the purity was confirmed with mass 
spectrometry, and the concentration determined by phosphate analysis [352]. Sources of other 
chemicals are found in the original publications I-III. 
 
Cell culture - Baby  hamster  kidney  (BHK21)  and  HeLa  cells  were  grown  in  cell  culture  flasks  
(Nunc, Roskilde Denmark) in DMEM (Gibco 41965) supplemented with 10% fetal bovine serum, 
2mM glutamine, penicillin (200 units/ml) and streptomycin (200 ug/ml) under 5% CO2 and 37°C. 
Wild type CHO-K1 cells were grown in HAM F-12 medium (Gibco 21765) with supplements as 
above. Human skin fibroblasts were grown in RPMI medium (Gibco) supplemented with 15% fetal 
bovine serum, 2 mM glutamine, penicillin (200 units/ml) and streptomycin (200 ug/ml). All cell 
culture media and supplements were from Gibco BRL (Life Technologies Inc. San Diego). For 
labelling, cells were plated 2-3 days prior to the experiment. The labelling and chase media were 
supplemented with 2% fetal bovine serum. 
 
Labelling cells with stable-isotope labelled precursors - Confluent monolayers of 
BHK21 or HeLa cells were washed once with PBS and then labelled with stable-isotope labelled 
serine or ethanolamine as specified in the original publications. In some experiments hydroxylamine 
(1.5 mM), an irreversible inhibitor of the PS decarboxylase [167, 210], was added to the culture 
medium. After the pulse, the cells were washed with PBS and chased in DMEM in the presence or 
absence of unlabelled serine (3 mM) and/or ethanolamine (1 mM). Cells were then washed 4 times 
with PBS and scraped into 250 mM sucrose or H2O.  
 
Introduction of labelled phospholipids to cells - Donor vesicles composed of a labelled 
phospholipid species, palmitoyl-oleyl-phosphatidylcholine and cholesterol (1:4:5 or 1:9:10 mol/mol) 
were introduced to cells in DMEM. A small amount (0.1%) of 22:0/22:0 phosphatidylcholine species 
was included in the donor vesicles to assess their binding to cells. Methyl-?-cyclodextrin (2-10 mM) 
was used as carrier to enhance the transfer of phospholipids from donor vesicles to cells.  
 
Lipid extraction - Lipids were extracted according to Folch et al. [353] except that 0.1 M HCl was 
used as the aqueous component and silylated glass tubes were used to maximize the recovery of PS. A 
mixture of internal standards was added at the single-phase stage of extraction for mass spectrometric 
quantification of the lipids. After evaporation of the solvents, the lipids were dissolved in 
chloroform/methanol (1:2, v/v) and stored at -20°C before the analysis. 
 
Mass spectrometry and data analysis - After addition of aqueous NH3 (4%), the sample was 
infused  at  6  ?l/min  to  the  ESI  source  of  a  Micromass  Quattro  Micro  triple-quadrupole  mass  
spectrometer (Waters), operated as previously [334]. The D9-PC, D4-PE, D3-PS and D315N-PS species 
and unlabelled PC, PE, PS, SM and phosphatidylinositol species were selectively detected using head 
group-specific precursor or neutral loss scanning [284, 354]. The species were identified and 
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quantified using the LIMSA software [333]. For identification of the acyl chain sn-positions of the 
endogenous species, as well as the remodelling products derived from the exogenous species, PE and 
PS classes were isolated by normal phase HPLC [351], and the individual species were then subjected 
to collisionally activated dissociation and product ion analysis [338, 355, 356]. 
 
Cell integrity - In the Trypan Blue exclusion test, the cells were first detached from culture dishes 
by Trypsin-EDTA and then pelleted by centrifugation. Trypan Blue (0.4%) in PBS was added to the 
pellet and the stained (leaky) cells were counted using a hemocytometer. To assess cell viability, cells 
were incubated with Alamar Blue in DMEM at 37 °C for 2 h. Then 200 ul of the media was pipetted 
to a 96-well plate and the fluorescence intensity was measured on Cary Eclipse fluorometer with the 
excitation and emission wavelengths set to 530 and 590 nm, respectively. The control samples 
included i) cells incubated in DMEM, ii)  cells  killed  with  70%  ETOH,  iii) cells killed with 5 mM 
CuSO4 and iv) DMEM. Protein content was determined by a fluorometric method employing 
fluorescamine [357] or by the method of Lowry et al. [358]. DNA was quantitated by using the Quant-
iT dsDNA Broad-Range Assay Kit (Molecular Probes) and cholesterol was determined with a 
cholesterol oxidase method [359]. 
 
Cell fractionation - HeLa cells grown on 14 cm dishes were detached from the dishes by 
Trypsin-EDTA and after washing with PBS and centrifugation (1500g, 2 min), the cells were 
suspended in 1ml of a mannitol (225 mM) - sucrose (75 mM) -Tris-HCl (30 mM) buffer, pH 7.4 and 
homogenized by passing 10 times through a 27G needle. 
 
A crude mitochondrial fraction was obtained by differential centrifugation as described [208, 360] and 
was further fractionated into the inner mitochondrial membrane (IMM) and the outer mitochondrial 
OMM fractions [309], except that 2 mg of digitonin was used per mg of mitochondrial protein. The 
supernatant from the crude mitochondrial fraction was further centrifuged at 20800 x g in order to 
pellet all debris. This supernatant contained the microsomes and cytosol (microsomal fraction). 
 
Immunoblotting – Western blotting with the following antibodies was used to assess the purity 
and cross-contamination of the subcellular fractions: calnexin (BD Biosciences) for ER/MAM; 
ACSL4 (Santa Cruz) for MAM; LAMP2 (Developmental Studies Hybridoma Bank) for lysosomes; 
VDAC (Calbiochem) for OMM and COXII (Santa Cruz) for IMM. Samples were pipetted on a 10% 
SDS-PAGE gel and transferred onto PVDF (Millipore) membranes. The target proteins were detected 
by using HRP-conjugated secondary antibodies and ECL+ (Amersham) detection reagent. 
 
RNA interference – Cells (300 000) were plated on 3cm dishes and siRNA treated with siRNA 
against Mitofusin 2 (MFN2), and\or Mitostatin (TCHP), or PSS1/2 proteins. Non-targeting siRNA was 
used as control. siRNAs were transfected without FBS using 5 ul of transfection reagent to a final 
consentration of 2 nM (MFN2, PSS1, PSS2) or 5 nM (TCHP) siRNA. 
 
Antibodies against Mitofusin 2 (Sigma Aldrich) and Mitostatin (Abgent) were used to detect the effect 
of siRNA on protein level, while RT-QPCR was used to determine the mRNA levels of MFN2, 
TCHP, PSS1 and PSS2. 
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RESULTS AND DISCUSSION 
(I) Introduction of intact phospholipids to cultured cells using me?-CD as a 
carrier  
Me?-CD mediated transfer of intact phospholipids 
 
An efficient method for the introduction of labelled phospholipids to cultured cells would be highly 
useful when studying PL remodelling and interorganelle translocation. Since certain CDs have been 
shown to efficiently transfer phospholipids from donor vesicles to cells, it appears they could be 
practical to use [266, 294]. Therefore we determined optimal labelling parameters in order to obtain 
efficient incorporation of exogenous phospholipids with similar hydrophobicity as the endogenous 
ones using me?-CD as a carrier. 
 
To asses the effects of me?-CD concentration we incubated BHK21 cells with donor vesicles 
containing either 14:1/14:1-, 16:1/16:1- or 18:1/18:1-PS. We found that the transfer of different PS 
species was enhanced with increasing cyclodextrin concentration (Fig. 6). However, the optimal CD 
concentration depended on the hydrophobicity of the phospholipid to be transferred. The less 
hydrophobic species, 14:1/14:1-PS, was efficiently transferred at 4-6 mM me?-CD while the more 
hydrophobic species, 18:1/18:1-PS, would apparently require higher me?-CD concentrations (>10 
mM) for efficient transfer. The transfer efficiency increased with time and maximal incorporation was 
usually obtained after 2-3 h. The results show that the transfer of exogenous phospholipids to cells 
depends greatly on the hydrophobicity of their acyl chains. The less hydrophobic the PL the more 
efficiently it is transferred by me?-CD.  
 
We also studied the influence of the polar head group, which as expected, had a rather small effect on 
transfer efficiency (I, Fig. 2). Next the efficiency of incorporation of exogenous phospholipids to 
different cell lines was studied and it was found to vary somewhat (I, Fig. 3). For example, various PE 
species were equally transferred to CHO, HeLa and HF cells, but less efficiently to BHK cells, 
whereas PS species were transferred more efficiently to CHO and HF cells than to HeLa and BHK 
cells. 
 
In previous studies phospholipid metabolism has been studied by incubating cells with radiolabelled or 
stable-isotope labelled precursors [284, 361]. However, these approaches do not allow studies of, for 
example, remodelling of single PL molecular species since numerous PL species become labelled 
already during the pulse. To overcome this problem intact phospholipids should be introduced to cells. 
Alternatively, PL species with short acyl chains, 6:0 or 8:0, or lysophospholipids could be introduced 
to cells, but even this is problematic, since rapid and potentially different metabolism of the short 
chain species from that of “natural” ones and uncontrolled reacylation of the lysophospholipids take 
place [362-365]. If one wants to introduce exogenous PLs with similar hydrophobicity to that of 
endogenous PLs a carrier is needed since they spontaneously move poorly into cells. Theoretically, 
phospholipid transfer proteins are ideal carriers, but they are inefficient resulting in the need for 
impractical amounts of such proteins [296, 297]. Another option could be fusion of vesicles with virus 
receptors [298]. Of the different cyclodextrins, carboxyethyl-?-cyclodextrin (?-CD) has been 
previously used in the introduction of pyrene labelled PLs to cells [266]. Use of me?-CD and donor 
vesicles enables efficient transfer of long-chain (phospho) lipids from vesicles to cells and, combined 
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with mass spectrometric analysis, lays a basis for detailed studies of phospholipid metabolism and 
trafficking. 
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Figure 6. Optimization of the labelling parameters – The labelling conditions for exogenous D-PS 
molecular species with varying molecular hydrophobicity were examined in BHK cells. The figure 
displays how increase in CD concentration (lane A), donor amount (lane B) and pulse time (lane C) 
affect the transfer of exogenous PS species from donor vesicles into cells as well as illustrates the 
effect of hydrophobicity in transfer efficiency. 
Risks in using me?-CD as a carrier 
 
Incubation of cells with me?-CD and donor vesicles could compromise cell viability e.g. by depleting 
cholesterol. Therefore we studied how incubation with me?-CD and donor vesicles affects cell 
integrity. 
 
We found that cell intactness or viability was not compromised even when rather high me?-CD 
concentrations (8 mM) were used. The morphology of the cells changed somewhat during the 
incubation and they were also more prone to detach from the dish than untreated cells. The growth of 
the “labelled” cells  was similar  to  that  of  the controls  based on protein and DNA determinations (I,  
Figs. 6 and 7). 
 
Since me?-CD is known to extract cholesterol from cells we studied if this can be prevented by 
addition of cholesterol in the donor vesicles. We incubated BHK21 cells with vesicles containing 0-
50% cholesterol. We found that cholesterol depletion could be almost fully compensated by addition 
of 50% cholesterol in the donor vesicles (I, Fig. 5). Besides cholesterol depletion, me?-CD may also 
deplete other lipids from cells. We observed some depletion of cellular sphingomyelin (SM), but the 
level of this lipid was normalized during the 24 h chase period (Fig. 7). The PC content of the cells 
was increased during the incubation with vesicles (which mainly consist of PC), but it was also 
normalized during a 24 h chase.   
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In previous studies me?-CD has been described to deplete cholesterol as well as other lipids from cells 
[301, 366, 367]. Our observations are consistent with these studies. In addition me?-CD has been 
reported to cause morphological changes in cells as well as cause leakage of LDH and inhibition of 
cell growth and cell cycle arrest [301, 368-370]. These harmful effects of me?-CD on cells, beside 
morphological changes, were not seen at incubation times and me?-CD concentrations needed for 
efficient transfer of hydrophobic exogenous PLs to cells, thus implying that this method does not 
affect the liability of obtained data.  
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Figure 7. Effect of me?-CD mediated transfer of exogenous PLs to cellular SM and PC – BHK21 
were labelled with exogenous PL and 8 mM me?-CD for 1 h and chased for 24 h. Panel A displays the 
relative amount of cellular sphingomyelin during the chase while panel B shows the relative amount of 
cellular PC expressed as % of total cellular PL.  
(II) Remodelling of phosphatidylserine and phosphatidylethanolamine 
species  
Remodelling of exogenous PE and PS 
 
In theory all phospholipid molecular species could be synthesized de novo. However, many of the 
endogenous molecular species are made by remodelling of existing ones, i.e. by changing one or both 
of the acyl chains of the remodelled phospholipid. We studied the remodelling of different exogenous 
PS and PE molecular species in BHK21 cells using the me?-CD mediated transfer and ESI-MS/MS 
analysis. 
 
We found that remodelling of exogenous PE and PS species in BHK21 cells was dependent on both 
the acyl chains and the head group. PE and PS molecular species that are normally absent or only 
minor components of the cellular PE and PS pools were rapidly and extensively remodelled (Fig. 8). 
For example, both 14:1/14:1-PE and PS were rapidly remodelled to natural species such as 18:1/18:1-
PE and 18:0/18:1-PS, respectively. In contrast, exogenous PE and PS species similar or identical to the 
major endogenous species, e.g.18:1/18:1 PE, were hardly remodelled at all. 
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We also found that the kinetics and sequence of sn1 versus sn2 remodelling were dependent on the 
acyl chains and head group. The PE species with a saturated acyl chain in the sn2 position were very 
rapidly remodelled at this position, whereas similar PS species were remodelled only at a moderate 
rate. The effect of acyl chain sn-position was strikingly demonstrated by studies with positional 
isomers. For example, while 14:0/18:1-PE was remodelled slowly, its positional isomer, 18:1/14:0 PE, 
was very rapidly and extensively remodelled in the sn2 position yielding several different species (II, 
Fig. 3). The sn1 position of PE species was found to be preferentially acylated with 16:1 and 18:1 
whereas in PS the preferred acyl chain was 18:0. Together these results indicate that the reacylation of 
PE and PS molecular species is conducted by different transacylases. 
 
Previously it has been shown that phospholipids are remodelled at both sn positions [287, 371]. Our 
data is consistent with these findings as seen from remodelling of e.g. 14:1/14:1-PS which was 
extensively remodelled yielding species (e.g. 18:0/18:1) that are a result of acyl chain change at both 
sn-positions. In addition it has been shown that the sn1 position of PS is preferentially acylated with 
18:0 [372] as was also found in our results. This preference also explains why PS with 18:0, or PE 
species with 16:1 or 18:1 in the sn1 position, were poor targets for PLA1 activity. In previous studies 
it has been shown that transacylase activity depends on the phospholipid head group [373, 374]. In 
agreement, the remodelling of corresponding PS and PE molecular species was found to be different. 
It is also known that endogenous PE normally do not contain saturated acyl chains at sn2 position [24, 
197] thus explaining the drastic difference in remodelling of PE positional isomers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Remodelling of exogenous PS molecular species – BHK cells were labelled with 14:1/14:1 
(left panel) or 18:1/18:1 D-PS (right panel) molecular species for 1 h and chased for the indicated 
times. In comparison spectra of the endogenous PS composition is shown in the bottom row.  
 
Remodelling of exogenous PLs illustrates the remodelling pathways for different molecular species. 
However, direct comparison with the remodelling of endogenous PLs should be done cautiously since 
for example the kinetics may vary due to that mixing of the exogenous PL to the endogenous PL pool 
takes some time despite relatively rapid intracellular trafficking [375]. Study of PL remodelling is 
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made feasible by using me?-CD mediated transfer of exogenous heavy-isotope labelled PLs to cells 
and mass spectrometric analysis. These tools provide detailed data on the remodelling pathways and 
kinetics of single molecular species. 
PLAs involved in remodelling of PS and PE 
 
The remodelling process involves PLA1 and PLA2 enzymes that hydrolyse the acyl chain from the 
respective sn-positions. The very different remodelling kinetics of corresponding PE and PS molecular 
species suggests that several different PLAs are involved in the remodelling of PE and PS.  To 
evaluate the role of different PLA2s in PE and PS remodelling, inhibitors against iPLA2? (S-Bel, 
MAFP), iPLA2? (R-Bel) and cPLA2 (MAFP) were employed. 
 
We found that MAFP was the most potent inhibitor of PE and PS remodelling, while R-Bel and S-Bel 
were less effective (Fig 9.). S-Bel inhibited the remodelling of 14:1/14:1-PS more efficiently than of 
14:1/14:1-PE, thus indicating different PLAs in remodelling of PE vs. PS.  Studies with other 
molecular species supported the idea that that several PLAs, able to distinguish between acyl chains 
and head groups, participate in the remodelling process (II, Fig. 5). For example remodelling of 
16:0/20:4-PS was not inhibited by any of the inhibitors while remodelling of 14:0/16:0-PS was almost 
completely inhibited by both R-Bel and S-Bel but not MAFP (II, Fig. 6). 
 
We also studied the effect of Triacsin C, an inhibitor of acyl-CoA synthases (II, Fig. 6).  Triacsin C 
did not affect PE remodelling, but intriguingly, inhibited remodelling of all PS species tested, thus 
suggesting that acyltransferases are involved in remodelling of PS but not PE. Lack of inhibition of PE 
remodelling by Triacsin C suggests that both sn-positions of this PL are reacylated by transacylases.  
 
The data obtained by using inhibitors of cPLA2, iPLA2? and iPLA2? support the role of these 
enzymes in the remodelling process of several PE and PS molecular species. However, the data 
suggests that also other, unidentified, PLAs participate in the remodelling process. 
 
To date only little is known about enzymes with PLA1 activity, but several PLA2 enzymes have been 
implicated in the remodelling process [216, 217, 324, 376, 377]. Previous studies have shown that 
distinct PLA2s show preference for PE or PC [228, 378], thus supporting the data obtained in this 
study that PLAs display head group specificity. Although PLA2 inhibitors, such as Bel and MAFP, are 
useful when studying the role of phopholipases in PL remodelling the results should be evaluated with 
caution since these inhibitors are not completely specific towards iPLA2 and cPLA2, respectively 
[315, 320, 321]. An alternative would be the use of RNA interference in order to identify individual 
phospholipases responsible for PL remodelling [216, 325, 326].  
 
Previous studies have shown that reacylation of the sn2 position of lysoPS in vitro is conducted by 
acyl-CoA-dependent acyltransferases/transacylases [379, 380]. Our data is in agreement with these 
observations since Triacsin C inhibited remodelling of sn2 position of  PS (II,  Fig.  6).  However,  the 
large variety of acyltransferases and their broad lyso-PL specificity complicates the task of specifying 
the single enzymes responsible for PL remodelling [261, 262]. 
 
The enzymes implicated in PL remodelling have been localized to several intracellular compartments 
including the ER, the Golgi, mitochondria, nucleus and peroxisomes [324, 376, 377, 381-387]. This 
intracellular distribution of the enzymes may contribute to the specific lipid compositions of 
organelles. The observed differences in remodelling of different PE and PS molecular species might 
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also be partially due to their differential intracellular trafficking and distribution [388]. In mammalian 
cells organelle specific remodelling has been found for PC [282]. Further studies are needed for 
elucidation of the speficic PLAs responsible for PL remodelling and for localization of the site of PL 
remodelling. 
 
14:1/14:1
 
 
CTRL
650 700 750 800 850 900
14:1/14:1
 
m/z
MAFP
 
Figure 9. The role of PLA2 enzymes in remodeling of exogenous PS – BHK cells were labelled with 
14:1/14:1 D-PS either with or without MAFP, an inhibitor of cPLA2 and iPLA2. The figure displays 
the  situation  after  a  1  h  pulse  and  a  30  min  chase.  The  peak  representing  the  introduced  D-PS  is  
indicated with a mark next to the peak. MAFP (lower panel) significantly inhibits remodelling of this 
PS molecular species as seen from the profiles of the spectra, i.e. relatively more of the precursor is 
present when MAFP was added and also the relative amounts of remodelling products (additional 
peaks) are smaller than without PLA2 inhibition. 
(III) Trafficking of phosphatidylserine and phosphatidylethanolamine 
molecular species to and from mitochondria  
Contribution of the PSD and Kennedy pathways to the cellular PE pool 
 
The cellular PE is derived from two pathways, the PS decarboxylation pathway and the Kennedy 
pathway. The PSD pathway produces PE by decarboxylation of PS in mitochondria whereas the 
Kennedy pathway synthesizes PE de novo. To study the contribution of these pathways to the total 
cellular PE pool we incubated HeLa cells with heavy-isotope labelled serine or ethanolamine under 
various conditions.  
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When HeLa cells were incubated for 24 h with D4-ethanolamine ~60%, of the total cellular PE pool 
consisted of the labelled species (Fig. 10). In contrast, 24 h incubation with labelled serine resulted in 
labelling ~20% of the total cellular PE pool. While these data seem to indicate that most of cellular PE 
is synthesized via the Kennedy pathway, analysis of the labelling of the intracellular serine and 
ethanolamine pools showed that the specific labelling of ethanolamine was significantly higher (up to 
6-fold, depending on incubation time) than that of serine (III, Fig. 1). When this was taken into 
account, the difference in specific labelling of the cellular PE pool via the two pathways was 
significantly reduced indicating that ~66% of cellular PE was derived from the Kennedy pathway and 
the rest from the PSD pathway (III, Fig. 1). 
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Figure 10. Specific labelling of the cellular PE pool by PSD and Kennedy pathways – HeLa cells were 
incubated for 24 h with heavy-isotope labelled serine or ethanolamine. The figure shows the specific 
labelling of the total cellular PE pool via PSD and Kennedy pathways, respectively. Differences in 
specific labelling of cellular serine or ethanolamine pools are not taken into account. 
 
We also found that the profile of the PE molecular species derived from PS differs significantly from 
the profile of PE species produced via the Kennedy pathway (III, Fig. 2). The most notable difference 
is that many polyunsaturated species (e.g. 38:4, 38:5 and 40:6) and the 36:1 species are more abundant 
in PE derived from the PSD pathway. On the other hand, the 32:1 and 32:2 species are more abundant 
in PE produced via the Kennedy pathway.  The profile of the endogenous PE species is more similar 
to that of serine labelled than ethanolamine labelled PE species. 
 
In earlier studies it has been shown that the contribution of the PSD and Kennedy pathways to the total 
cellular PE pool varies between cell lines as well as between intracellular organelles [3, 197]. In 
agreement,  our  data  indicate  that  in  HeLa  cells  the  contribution  by  the  Kennedy  pathway  to  the  PE  
pool is somewhat higher even when the higher specific labelling of the cellular ethanolamine pool is 
taken into account [82, 197].  
 
It has also been shown that the PSD and Kennedy pathways provide cells with different PE molecular 
species [197]. Accordingly, in HeLa cells these two pathways seem to produce the same subset of PE 
molecular species, but in different proportions (III, Fig. 2). Interestingly, the cellular PE pool reminds 
us more of the PE composition derived from PSD pathway even though a majority of the cellular PE 
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seems to be derived from the Kennedy pathway. Why two different biosynthetic routes are needed is 
not  clear  but  the  PE  from  PSD  pathway  has  been  indicated  to  be  crucial  for  the  function  of  
mitochondria [208, 209], thus explaining one function of the PSD route. In addition, it is known that 
mammalian cells cannot synthesize ethanolamine de novo and thus require supplementation of 
ethanolamine from culture media, from degradation of PE derived from PS, or to some degree from 
degradation of sphingolipids [187]. The restricted supply of ethanolamine could direct the synthesis of 
PE to be conducted via the PSD pathway, thus also potentially explaining the resemblance of the 
endogenous PE pool to that derived from the PSD pathway (III, Fig. 2). In accordance, we found that 
supplementating HeLa cells with ethanolamine stimulated synthesis of PE by the Kennedy pathway. 
Import of PS to mitochondria and export of PE therefrom 
 
A large part of the cellular PE pool is derived from the PSD pathway. In addition, in mammalian cells 
PS decarboxylase is explicitly located in the inner mitochondrial membrane. Thus, PS must be 
imported to mitochondria in order to be decarboxylated. To study this import process we first 
introduced D4- labelled exogenous PS species to HeLa cells using me?-CD as a carrier. 
 
We found that the exogenous PS species were decarboxylated at very different rates. The 16:1/16:1 
species was decarboxylated rapidly, i.e. close to 60% was decarboxylated during the first 2 h (Fig. 11 
A). Although this species is less hydrophobic than the major endogenous PS species, e.g. 16:0/18:1 
and 18:0/18:1, its efficient decarboxylation demonstrates that PSD has a high capacity to 
decarboxylate PS molecules entering the IMM. As expected the decarboxylation was less efficient for 
16:0/18:1 apparent due to it being more hydrophobic than 16:1/16:1-PS. Surprisingly, the 
polyunsaturated 18:0/20:4 species was decarboxylated faster than predicted based on its 
hydrophobicity, i.e. its hydrophobicity should be close to that of 16:0/18:1. 
 
We next studied the translocation of endogenous PS species. The cells were incubated with D-labelled 
serine for 4 h and then chased for a further 8 h. Major differences in the rate of decarboxylation among 
different PS species were found. The most rapid decarboxylation was observed for the polyunsaturated 
species 38:4 and 38:5, while the 34:2, 36:1 and 40:6 species were decarboxylated at a significantly 
slower rate (III, Fig. 3). No clear correlation between the rate of decarboxylation and the molecular 
hydrophobicity was found, but rather a dependence on the acyl chain composition. 
 
Transport of PS to mitochondria has been indicated to occur via membrane contact sites between the 
MAM and the mitochondria. To study this we used RNA interference to knock-down Mitofusin 2 
and/or Mitostatin proteins that have been indicated to participate in MAM-mitochondria contact sites 
in mammalian cells [104, 117]. However, we did not find any difference in decarboxylation between 
control and knock-down cells. 
 
To study the export of PS derived PE from mitochondria we first labelled HeLa cells with exogenous 
D4-PS species and then isolated the IMM and microsomal fractions. Translocation of PE species 
derived from exogenous PS from mitochondria to microsomes also varied significantly (Fig. 11 B). As 
can be seen in Fig. 11 B the most efficient translocation of the three molecular species presented, was 
observed for the di-16:1 species, i.e. ~20% of this species was found in microsomes at or soon after 
the end of the pulse. Interestingly the least efficient transfer was observed for the 18:0/20:4 PE 
species, which was imported as PS into mitochondria more efficiently than expected.  
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The export of PE derived from endogenous PS was studied by labelling HeLa cells for 3 h with D-
labelled serine and subsequent isolation of IMM and microsomal fractions. After the 3 h incubation 
with D-labeled serine ~4% of the PE in IMM was labelled, while only ~1.5% of the microsomal PE 
pool consisted of the labelled species (III, Fig. 4). After 24 h of chase the amount of specific labelling 
in the microsomal fraction had increased to ~4%. The time-dependent redistribution of PS-derived PE 
from mitochondria to microsomes is clearly illustrated by the fact that during the chase the fraction of 
cellular D-PE in microsomes increased 2-fold (from ~9% to ~22%) while that in IMM decreased 
correspondingly from ~29% to ~13% (III, Fig. 4). These data demonstrate that PE derived from PS in 
mitochondria is effectively exported from mitochondria.  
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Figure 11. Import of exogenous PS to mitochondria and export of PE therefrom – HeLa cells were 
labelled with the indicated exogenous D-PS molecular species for 45 min (16:1/16:1) or 1 h and 
chased  for  up  to  8  h  and  IMM and  microsomal  fractions  were  isolated.  Panel  A  shows  the  relative  
amount of D-PE out of the total D-PL thus displaying the decarboxylation and translocation of the 
particular D-PS molecular species to mitochondria. Panel B displays the relative amount of indicated 
D-PE, derived from corresponding exogenous D-PS, in microsomes out of the total cellular amount of 
the particular D-PE molecular species. 
 
All PS-derived PE molecular species were transported from IMM to microsomes, but at significantly 
different rates. The 32:2 (16:1/16:1) species was most efficiently transported, i.e. almost half of the 
cellular pool of this lipid was found in microsomes after a 24 h chase. Also the 34:2 and 38:6 species 
were translocated more efficiently than the remaining ones. Interestingly, in agreement with results 
obtained with exogenous PS species, the 18:0/20:4 molecular species was translocated only modestly 
even though it was efficiently decarboxylated (III, Fig. 5). 
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Previously it has been stated that, depending on cell type the majority of the cellular PE would be 
derived from the PSD pathway [80, 168, 194, 195, 208], thus indicating that PS is transported from its 
site of synthesis in ER/MAM [112, 166, 272] to mitochondria. This transport has been studied for 
example by using exogenous pyrene labelled PS species and 3H-serine [81, 82, 87, 111, 167, 208, 266, 
268, 270, 354]. It has been indicated that the transport is ATP-dependent, that newly made PS is 
preferentially translocated and that the transport rate of PS molecular species depends on the 
hydrophobicity [167, 266, 270, 330, 354]. Accordingly, we found that the less hydrophobic exogenous 
PS molecular species were decarboxylated, i.e. translocated to mitochondria, more efficiently than 
those with higher hydrophobicity, with the exception of the decarboxylation rate higher than expected 
for 18:0/20:4. However, this was not found to be the case with decarboxylation of newly synthesized 
PS species. We found that molecular species 38:4 and 38:5 were decarboxylated with higher 
efficiency than expected based on their estimated hydrophobicity (III, Fig. 3). When comparing mono- 
and diunsaturated molecular species with the same acyl chain length it was found that in general the 
species with two double bonds, i.e. less hydrophobic ones, were more efficiently decarboxylated. In 
earlier studies it has been suggested that the PSD pathway would preferentially produce distinct PE 
species and that the PSD would have some substrate specificity [197-200]. However, our data suggests 
that the PSD and Kennedy pathways produce the same PE species but in different ratios. The 
decarboxylation of newly synthesized PS species did not directly correlate with molecular 
hydrophobicity, but rather it was dependent on the acyl chain composition of the individual molecular 
species. The mechanism behind this remains unclear. 
 
As stated previously, the translocation of PS to mitochondria is ATP-dependent, not vesicle mediated, 
but rather due to spontaneous diffusion [82, 167, 266, 268, 330, 354]. Since PS is synthesized in the 
ER, more closely in the MAM, it has been thought that PS could be translocated to mitochondria via 
close appositions between the MAM and mitochondria [87, 111, 112, 167, 208]. These contact sites 
are suggested to be maintained by proteins or protein complexes. Two proteins implicated to play 
important role in the contact site formation between the mitochondria and the MAM are Mitofusin 2 
and Mitostatin [104, 117]. In fact, yeast cells with mutated proteins in the ERMES complex, a 
complex maintaining ER-mitochondria junctions, displayed a slower flow of phospholipids to 
mitochondria and lower abundance of mitochondrial PE [116]. However, the transport of PLs to 
mitochondria was not totally inhibited. Homologues for ERMES proteins in mammalian cells have not 
been identified thus complicating studies of the role of similar ER-mitochondria contact site 
complexes. However, the Mitofusin 2 and Mitostatin proteins implicated to participate in contact site 
formation in mammalian cells could be knocked-down by RNA interference. As seen from our results, 
Mitofusin 2 or Mitostatin do not appear to participate in ER-mitochondria contact site function 
mediating PS translocation to mitochondria (III, Supplement Fig. 3). To elucidate the role of contact 
sites in PS translocation to mitochondria, more contact site proteins need to be identified. 
 
Only a few studies have addressed the export of PE from mitochondria although the majority of 
cellular PE could be derived from PS [208, 270, 389]. PE formed in mitochondria is translocated to 
ER and the transport is independent of cytosolic proteins and not stimulated by exogenous ATP [208, 
270]. In agreement with these results our data confirm translocation of PE derived from PS to 
microsomes (III, Fig. 4). In addition our data indicated that there is selectivity in transport of different 
molecular  species  (III,  Figs 5 and 6).  However,  the mechanism behind this  selectivity remains to be 
elucidated. 
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Import of PE to mitochondria 
 
Since mitochondria can synthesize PE via decarboxylation of PS they may in theory obtain their PE 
pool from this pathway only. Therefore we studied if PE synthesized by the Kennedy pathway is 
imported to mitochondria and what the contribution of this route is to the mitochondrial PE pool. 
To study this we incubated HeLa cells with D4-ethanolamine and isolated the IMM and microsomal 
fractions. We found that after a 1 h pulse, ?60% of the cellular D4-PE was found in microsomes and 
only ~2% in the IMM (III, Fig. 8). When the cells were then chased for 24 h in the presence of 
unlabelled ethanolamine, the microsomal fraction of labelled PE remained constant, while that in IMM 
doubled, but was still very low, i.e. ?4%.  These  data  indicate  that  PE  synthesized  in  the  ER  
translocates poorly to mitochondria.  
 
When the D4-PE molecular species compositions of microsomes and IMM were studied they were 
found to be nearly identical. In addition, the time-dependent changes in D4-PE compositions in the two 
fractions were close to being identical (III, Supplement Fig. 4). These data and the fact that the IMM 
fractions could not be totally purified from the MAM and lysosomal contaminants indicate that the 
actual amount of translocated D4-PE is even smaller than calculated.  
 
Previous studies have shown that PE synthesized by the Kennedy pathway in the ER [166, 190, 192] is 
transported to the PM in a similar fashion as PC and PS [79]. However, contradictory data have been 
presented about translocation of PE from ER to mitochondria [197, 208, 276]. Our data supports the 
suggestion that PE synthesized in the ER is transported to mitochondria inefficiently. In fact, as stated 
previously, most of the mitochondrial PE seems to be derived from the PSD pathway which also 
seems to be crucial for the function of the organelle [197, 208, 209].  
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CONCLUSIONS 
 
Metabolism and translocation of PE and PS were studied. The following main conclusions were 
drawn: 
 
? We showed that me?-CD is an efficient carrier of exogenous phospholipids to cultured 
cells and that the developed method does not affect cell viability. The efficacy of me?-CD 
mediated transfer of heavy-isotope labelled phospholipids is dependent on the molecular 
hydrophobicity, pulse time and cyclodextrin concentration. The vesicular cholesterol 
concentration is crucial in order to compensate cholesterol depletion by me?-CD. The 
method developed enables e.g. extensive manipulation of cellular PL composition, and is 
thus useful when studying mechanisms contributing to PL homeostasis. 
? By using heavy-isotope labelled phospholipids we showed that the remodelling pathways 
of PS and PE and their kinetics are highly dependent on the acyl chain composition as 
well as the polar head group of the phospholipid. The remodelling process is conducted by 
several different phospholipases targeting both sn1 and sn2 positions, in addition to 
acyltransferases and transacylases. The phospholipases are selective over different 
molecular species and phospholipid classes. Tha data obtained lays a basis for future 
studies to elucidate both the processes and the proteins involved in maintenance of PL 
homeostasis. 
? The Kennedy and PSD pathways of PE synthesis provide the same molecular species but 
in different ratios. The import of PS to and export of PE from mitochondria are not 
directly related to the molecular hydrophobicity, but rather to the acyl chain composition 
of  the  PS  and  PE  species.  The  import  of  newly  synthesized  PS  to  mitochondria  is  not  
affected by knock-down of the MAM-mitochondria contact site proteins Mitofusin 2 and 
Mitostatin. 
? Heavy-isotope labelled precursors/phospholipids and mass spectrometry employing class-
specific scans is a powerful tool to study phospholipid metabolism. Highly detailed data 
of time-dependent synthesis, remodelling and transport of single PL molecular species can 
be obtained by using this approach. 
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